Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first month of 2025 suggested it would be a big year for high-priced transactions in the biopharma industry. But it was a false alarm. But later in the year, when drugmakers gained more clarity on the new regulatory and pricing landscape, the M&A market heated up. Of the 10 largest transactions executed in 2025, eight came in the second half of the year, with six of those deals in the fourth quarter. Will the trend continue in 2026? Many industry watchers—based on what they saw in Q4—believe the market is primed for a banner year for M&A.
Read the full article: 2026 Forecast: After a Surge of Biopharma M&A in Q4, Will the Trend Continue? //
Source: https://www.fiercepharma.com/pharma/2026-forecast-after-surge-ma-q4-will-trend-continue-next-year